Abstract
We have tested the recombinant human adenosine deaminase (hADA) retroviral vector MFG-ADA for its efficacy in transducing hemopoietic stem cells of nonhuman primates and its expression level in the hematopoietic system. The percentage of provirus-positive granulocytes 1 year after transplantation of bone marrow transduced with MFG-ADA was 0.1%, which was equivalent to previously obtained results with the hADA virus-producing cell line POC-1. However, in MFG-ADA monkeys, significantly more peripheral blood mononuclear cells carried the hADA gene (1% versus 0.1%). Human ADA expression levels in peripheral blood mononuclear cells were different between POC-1 and MFG-ADA monkeys using samples with equal numbers of provirus copies per cell. In contrast, in total red blood cell lysates of MFG-ADA monkeys, the hADA expression was higher (approximately 10-fold) and could be detected longer (20 weeks and up to more than 1 year after bone marrow transplantation in 2 monkeys) than in POC-1 monkeys that were only positive for up to 12 weeks at the most. At 3 years after bone marrow transplantation, the MFG-ADA provirus could still be detected in 0.1% of bone marrow cells and peripheral blood cells and in 1% of cultured T cells. These results show that MFG-ADA virus can give rise to long-term in vivo expression of hADA in the primate hematopoietic system. However, transduction efficiencies remain low.
Original language | English |
---|---|
Pages (from-to) | 1605-10 |
Number of pages | 6 |
Journal | Human gene therapy |
Volume | 8 |
Issue number | 13 |
DOIs | |
Publication status | Published - 1 Sept 1997 |
Keywords
- 3T3 Cells
- Adenosine Deaminase/genetics
- Animals
- Bone Marrow Transplantation
- Coculture Techniques
- Genetic Vectors
- Hematopoietic Stem Cells/enzymology
- Humans
- Lymphocyte Depletion
- Macaca mulatta
- Mice
- Transduction, Genetic